Related Topics News - Drugs

     
 Title only   |   Print    Next page > 
     
綠葉製藥溢價24.9%發行1.8億美元可轉債 擬同步回購2028年到期可轉債

2026-06-04T  
《大行》大摩降微創醫療目標價至10.5元 維持「與大市同步」評級

2026-05-21T  
聯邦制藥UBT38006注射液獲臨床試驗默示許可

2026-05-07T  
《大行》大摩:上海醫藥首季業績符預期

2026-05-05T  
《大行》高盛升上海醫藥目標價至10.63元 維持「沽售」評級

2026-05-05T  
微創醫療附屬心脈醫療首季賺1.55億人民幣 增長19.4%

2026-04-29T  
《業績》上海醫藥首季歸屬淨利潤按年增長6.35%

2026-04-29T  
聯邦制藥TUL321膠囊臨床試驗申請獲FDA批准

2026-04-28T  
上海醫藥潑尼松龍片通過仿製藥一致性評價

2026-04-27T  
《大行》大摩降上海醫藥目標價至15.8元 評級「增持」

2026-04-24T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.